Recent Quotes
My Watchlist
Indicators
New Hampshire Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

argenx SE - American Depositary Shares (NQ:ARGX)

818.50 -1.86 (-0.23%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about argenx SE - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Insmed Catapults While IBD 50's Argenx Creeps Higher On Bullish Reports
Insmed stock surged early Thursday as Argenx stock rose more moderately. The top-notch biotech companies beat third-quarter calls. 
Via Investor's Business Daily
Earnings Scheduled For October 30, 2025
 
Via Benzinga
argenx Reports Third Quarter 2025 Financial Results and Provides Business Update
From argenx SE
Via GlobeNewswire
argenx Presents New Data at AANEM and MGFA Highlighting the Strength and Broad Benefit of VYVGART for Myasthenia Gravis Patients
From argenx SE
Via GlobeNewswire
ARGENX SE - ADR (NASDAQ:ARGX) Shows Strong Growth Traits Matching Navellier's Criteria
Argenx SE shows strong earnings momentum, soaring revenue growth, and high profitability, aligning with Louis Navellier's systematic growth stock criteria. 
Via Chartmill
How Do Investors Really Feel About argenx SE?
 
Via Benzinga
12 Analysts Have This To Say About argenx
 
Via Benzinga
Is argenx Gaining or Losing Market Support?
 
Via Benzinga
argenx to Report Third Quarter 2025 Financial Results and Business Update on October 30, 2025
From argenx SE
Via GlobeNewswire
If You Invested $1000 In argenx Stock 5 Years Ago, You Would Have This Much Today
 
Via Benzinga
Checking In on The Trade Desk, Bristol Myers Squibb, and Other Stocks
Motley Fool analysts Karl Thiel, Rick Munarriz, and Tim Beyers offer up three stocks that face dark clouds they can see through. 
Via The Motley Fool
Topics Workforce
argenx to Highlight Key Data and Breadth of Immunology Innovation at 2025 AANEM Annual Meeting and MGFA Scientific Session
From argenx SE
Via GlobeNewswire
Assessing argenx: Insights From 12 Financial Analysts
 
Via Benzinga
Tesla To $300? Here Are 10 Top Analyst Forecasts For Monday
 
Via Benzinga
argenx announces Extraordinary General Meeting of Shareholders on November 18, 2025
From argenx SE
Via GlobeNewswire
ARGENX SE - ADR (NASDAQ:ARGX) Matches a Proven Growth Stock Strategy
ARGENX stock matches a proven growth strategy, showing explosive earnings revisions, 731% EPS growth, and strong revenue momentum. 
Via Chartmill
Here's How Much $100 Invested In argenx 5 Years Ago Would Be Worth Today
argenx (NASDAQ: ARGX) has outperformed the market over the past 5 years by 7.61% on an annualized basis producing an average annual return of 22.36%. Currently, argenx has a market capitalization of... 
Via Benzinga
Price Over Earnings Overview: argenx
In the current market session, argenx Inc. (NASDAQ: ARGX) share price is at $711.62, after a 0.07% increase. Moreover, over the past month, the stock decreased by 0.08%, but in the past year, went up... 
Via Benzinga
Pharma Tariffs Back In Spotlight On New Trump Threat
President Donald Trump threatened 100% tariffs on some drug imports. 
Via Investor's Business Daily
Topics ETFs Government World Trade
Johnson & Johnson Unleashes Triple Threat: Bladder Cancer Breakthrough, Psoriasis Game-Changer, and Myasthenia Gravis Milestone Signal New Pharma Era
Johnson & Johnson (NYSE: JNJ) is making significant waves in the pharmaceutical landscape, announcing a trio of pivotal developments that underscore its robust pipeline and strategic focus on unmet... 
Via MarketMinute
$1000 Invested In argenx 5 Years Ago Would Be Worth This Much Today
 
Via Benzinga
argenx SE - ADR (NASDAQ:ARGX) Fits Louis Navellier's 'Little Book' Growth Strategy
Discover argenx SE (ARGX), a top growth stock meeting Louis Navellier's strict criteria with surging earnings, 97% revenue growth, and strong profitability. 
Via Chartmill
United Therapeutics Price Strength Rating Jumps After Its Stock Soared 33% Last Week On Positive Drug Test Results
United Therapeutics also boasts a terrific 96 Composite Rating. The Composite score combines five separate proprietary ratings into one. 
Via Investor's Business Daily
Topics ETFs
Why Dianthus Therapeutics, Up 47% In Four Weeks, Just Surged Again
The company is working on a treatment for an autoimmune disease that affects the muscles. 
Via Investor's Business Daily
3 Healthcare Pathbreakers With Long-Term Tailwinds
These three firms in the fast-changing healthcare sector stand out to analysts for their strong product lineups, defensible technology, and notable pipelines. 
Via MarketBeat
argenx to Present at Upcoming Investor Conferences
From argenx SE
Via GlobeNewswire
Here's How Much $100 Invested In argenx 5 Years Ago Would Be Worth Today
 
Via Benzinga
Argenx Immune Disorder Drug's Reach Could Get Much Bigger With Major Trial Win
Argenx advances Vyvgart with strong trial data in seronegative gMG, driving growth projections and reinforcing its leadership in IgG-driven diseases. 
Via Benzinga
Regeneron Advances In Rare Disease Race With Positive Autoimmune Muscle Disorder Trial Data
Regeneron's Phase 3 NIMBLE trial showed cemdisiran improved myasthenia gravis symptoms, with an FDA filing expected in early 2026. 
Via Benzinga
Argenx Stock Hits Record High After Reporting 664% Earnings Surge; This Rating Upgraded
Additionally, the IBD SmartSelect Composite Rating for Argenx stock rose from 94 to a near best 96 Tuesday. 
Via Investor's Business Daily
Topics ETFs
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.